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ABSTRACT
Background    Cardiac fibrosis is considered to be a 
crucial factor in the development of heart failure. Block-
ade of the mineralocorticoid receptor (MR) attenuated 
cardiac fibrosis and improved the prognosis of patients 
with chronic heart failure but the ligand for MR and the 
regulatory mechanism of MR pathway in the diseased 
heart are unclear. Here, we investigated whether gluco-
corticoids can promote cardiac fibrosis through MR in 
oxidative stress and the involvement of elongation factor 
eleven-nineteen lysine-rich leukemia (ELL), a co-activa-
tor of MR, in this pathway. 
Methods and Results    The MR antagonist eplerenone 
attenuated corticosterone-induced collagen synthesis as-
sessed by [3H]proline incorporation in rat neonatal cul-
tured cardiac fibroblasts in the presence of H2O2, as an 
oxidative stress but not in the absence of H2O2. H2O2 in-
creased the ELL expression levels and MR-bound ELL. 
ELL expression levels and MR-bound ELL were also 
increased in the left ventricle of heart failure model rats 
with significant fibrosis and enhanced oxidative stress. 
Eplerenone did not attenuate corticosterone-induced 
increase of [3H]proline incorporation in the presence of 
H2O2 after knockdown of ELL expression using small 
interfering RNA in cardiac fibroblasts. 
Conclusion    Glucocorticoids can promote cardiac fi-
brosis via MR in oxidative stress, and oxidative stress 
modulates MR response to glucocorticoids through the 
interaction with ELL. Preventing cardiac fibrosis by 
modulating glucocorticoid-MR-ELL pathway may be-
come a new therapeutic strategy for heart failure. 
 
Key words    co-activator; corticosterone; eplerenone; 
heart failure 
 
Blockade of the mineralocorticoid receptor (MR) im-
proved mortality of patients with chronic heart failure 
(HF)1, 2 and was effective in the reduction of myocardial 
damage even in HF patients with low to normal aldo-
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sterone levels.3, 4 However, the mechanism underlying 
the benefits of MR-blockade in those HF patients is still 
unclear. 
 In typical aldosterone targets such as renal, tubular 
or vascular smooth muscle cells, 11beta-hydroxysteroid 
dehydrogenase type II (11betaHSD2) converts glucocor-
ticoid to inactive form, and thus aldosterone can exert 
specific actions on MR.5 In contrast, in several non-ep-
ithelial tissues such as heart, expression of 11betaHSD2 
is negligibly low.5, 6 The physiological glucocorticoids 
are corisol in humans and corticosterone in rodents and 
they have similar affinity for MR as aldosterone.7 Car-
diac MRs are overwhelmingly occupied by glucocorti-
coids rather than by aldosterone.8 High serum levels of 
cortisol, the major glucocorticoid in humans are an inde-
pendent predictor of increased mortality risk in patients 
with HF.9 We have shown that administration of eplere-
none, an MR antagonist, attenuates cardiac fibrosis and 
prevents HF in hypertensive HF Dahl salt-sensitive rats, 
with corticosterone levels in the left ventricule (LV) 
approximately 800 times those of aldosterone.6 This 
suggests that corticosterone acts as an MR agonist and 
promotes cardiac fibrosis which plays an important role 
in the development of HF.10, 11 It has been postulated that 
if intracellular redox state changes with tissue damage 
and the generation of reactive oxygen species (ROS), the 
physiological glucocorticoids act as MR agonists.12–14 
Serum cortisol has also been reported as a useful predic-
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tor of cardiac events in patients with HF in the presence 
of oxidative stress.15 However, it is still unclear whether 
glucocorticoids promote cardiac fibrosis via MR in oxi-
dative stress and the mechanisms.
 Elongation factor eleven-nineteen lysine-rich leu-
kemia (ELL) was reported to bind to MR and increase 
MR activity in response to glucocorticoids as well as to 
mineralocorticoids as a co-activator of MR.16 Therefore, 
ELL may be involved in glucocorticoid promotion of 
cardiac fibrosis via MR but the function in the diseased 
heart has not to be determined.
 Here, we investigated whether glucocorticoid could 
promote cardiac fibrosis via MR in oxidative stress. In 
addition, the role of ELL in glucocorticoid-induced car-
diac fibrosis via MR was investigated.
 
MATERIALS AND METHODS
This study was approved by the institutional ethics 
committee of Osaka University Graduate School of 
Medicine (Approval Number: 23-014-0, 23-030-1, 23-
062-0), and conforms to the Guide for the Care and Use 
of Laboratory Animals published by the United States 
National Institutes of Health.
 
HF model rats
Male Dahl salt-sensitive rats (Japan SLC, Shizuoka, 
Japan) fed on 8% NaCl diet from 6 weeks old as HF 
group (n = 8) and male Dahl salt-sensitive rats fed on 
0.3% NaCl diet throughout the study protocol as an age-
matched control group (n = 8) were used for this study.17 
This model presents HF around 19 to 20 weeks of age 
with significant cardiac fibrosis.18, 19 Rats were sacrificed 
in 22 weeks of age with established HF. Anesthesia 
included ketamine HCl (80 mg/kg, intraperitoneally) 
and xylazine HCl (10 mg/kg, intraperitoneally) and its 
adequacy monitored by the stability of blood pressure, 
heart rate, and lack of flexor responses to paw-pinch.20 
The heart and lungs were rapidly harvested, and LV and 
lung weight corrected for tibial length. The LV was im-
mediately placed in liquid nitrogen and stored at −80 
˚C for real-time quantitative reverse transcriptase-PCR 
(RT-qPCR) and Western blot analysis. LV samples were 
fixed with a phosphate-buffered 10% formalin solution 
for Azan-Mallory staining, and embedded in Tissue-Tek 
O.C.T. compound (Sakura Finetechnical, Tokyo, Japan) 
on dry ice for immunohistochemistry.
 
Histological analysis
Azan Mallory staining was performed on LV transverse 
sections to evaluate LV fibrosis as previously described.18
 To evaluate oxidative stress in the LV of the HF rats, 
tissue sections were incubated with mouse monoclonal 
anti-4-hydroxy-2-nonenal (HNE) antibody (1:50 dilu-
tion; NOF Medical Department, Tokyo) as previously 
described.18
 
Cultured cardiac fibroblasts 
Neonatal rat cardiac fibroblasts were isolated from 
Wistar rats by standard techniques with some modi-
fication of the previously described method.21 Briefly, 
neonatal rats were deeply anesthetized by inhalation of 
5% sevoflurane until loss of paw withdrawal reflex was 
obtained. After cervical dislocation was performed, they 
were opened by sternotomy and their hearts removed. 
LV samples from neonatal rats were cut into pieces of 
approximately 1 mm3 with scissors and subjected to 
collagenase (Wako Pure Chemical Industries, Osaka, 
Japan) digestion in phosphate-buffered saline. Dispersed 
cells were incubated on 100 mm culture dishes for 40 
min in a 5% CO2 incubator. Non-myocytes attached to 
the bottom of the dishes were subsequently incubated 
with Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
calf serum (FCS) (26140, Invitrogen) for an additional 
48 h.  Confluent cardiac fibroblasts were treated with 
0.05% trypsin-EDTA (Invitrogen) and subcultured. 
Virtually pure fibroblast cultures were confirmed by 
immunostaining with a monoclonal anti-vimentin (V9) 
antibody (1:250 dilution; sc-6260, Santa Cruz Biotech-
nology, Dallas, TX).22 Cells were passaged twice and 
incubated in DMEM supplemented with 10% charcoal 
stripped FCS (12676, Invitrogen). The medium of sub-
confluent cells of the second passage was changed to 
DMEM without FCS 24 h before H2O2 administration (1 
μmol/L; Wako Pure Chemical Industries), corticosterone 
(300 nmol/L; Sigma-Aldrich, St. Louis) or eplerenone (1 
μmol/L; Tocris Bioscience, Ellisville, MO).
 
Western blot analysis
The protocol of Western blot analysis was the same as 
previously described.18, 19 LV tissue was homogenized 
in buffer (50 mM Tris-HCl, 0.1 mM sodium orthovana-
date, 50 mM sodium fluoride, 150 mM sucrose, 1 mM 
benzamide, 5 mM EDTA and 2 mM EGTA) supple-
mented with protease inhibitor cocktail (Thermo Sci-
entific, Waltham, MA). Cells were lysed with buffer (50 
mM Tris-HCl, 0.1 mM sodium orthovanadate, 50 mM 
sodium fluoride, 150 mM sucrose, 1 mM benzamide, 
5 mM EDTA, 2 mM EGTA and 1% Triton X-100) 
supplemented with the protease inhibitor cocktail. After 
centrifugation, the supernatant protein concentration 
was determined by the Lowry’s method. Aliquots were 
mixed with equal volumes of Laemmli buffer (250 mM 
Tris-HCl, 20% glycerol, 4% sodium dodecyl sulfate, 
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10% 2-mercaptoethanol and 0.01% bromophenol blue), 
heated for 5 min at 95 ˚C, subjected to electrophoresis 
on 7.5% SDS-PAGE and then transferred to Immobilon-
P Transfer membranes (Millipore, Billerica, MA). The 
membrane was then incubated with rabbit polyclonal 
primary antibodies for ELL (1:200 dilution; sc-28702; 
Santa Cruz Biotechnology), MR (sc-11412; Santa Cruz 
Biotechnology) or glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (1:2000 dilution; sc-25778; Santa 
Cruz Biotechnology) at 4 ˚C overnight, followed by sec-
ondary antibody [111-035-144; peroxidase-conjugated 
AffiniPure goat anti-rabbit immunoglobulin G (H + L), 
Jackson ImmunoResearch Laboratories, West Grove, 
PA] at room temperature for 1 h. Blots were developed 
by enhanced chemiluminescence and expression levels 
quantified with LAS-4000 and MultiGauge software 
(Fujifilm, Tokyo). The band density of the protein of in-
terest was normalized to GAPDH expression.20
 
RT-qPCR
Total RNA was extracted from the LV samples and car-
diac fibroblasts stored at –80 ˚C and reverse-transcribed 
with oligo d(T)16 as a reverse primer as previously 
described.23 RT-qPCR with the ABI PRISM 7900 HT 
Sequence Detection System and Software Version 2.3 
(Applied Biosystems, Foster City, CA) was conducted to 
measure mRNA levels. The sequence of the primers and 
TaqMan probe for GAPDH were previously described.24 
The primers and TaqMan probes for ELL, and MR were 
Fig. 1.  [3H]proline incorporation into cardiac fibroblasts under oxidative stress. 
A: Cardiac fibroblasts were treated with Cor (300 nmol/L) and/or Epl (1 μmol/L) in 
the absence of H2O2. Untreated cardiac fibroblasts were served as control. n = 8 
for each group.  
B: Cardiac fibroblasts were treated with Cor (300 nmol/L) and/or Epl (1 μmol/L) 
in the presence of H2O2 (1 μmol/L). Cardiac fibroblasts treated with H2O2 alone 
were served as control. n = 8 for each group. 
Control was arbitrarily set to 1. Data are expressed as mean values ± SD. 
*P < 0.05 versus control. 
†P < 0.05 versus Cor (+) Epl (–). 
#P < 0.05 versus Cor (–) Epl (+). 
Cor, corticosterone; Epl, eplerenone. 
assays-on-demand gene expression products (assay ID 
Rn01420173_g1 and Rn00492539_m1, respectively; 
Applied Biosystems). The amount of each mRNA was 
divided by that of GAPDH mRNA to correct for the ef-




Samples were homogenized with immunoprecipita-
tion (IP) buffer (50 mM Tris-HCl, 0.1 mM sodium or-
thovanadate, 50 mM sodium fluoride, 150 mM sucrose, 
1 mM benzamide, 5 mM EDTA, 2mM EGTA and 1% 
Triton X100) supplemented with the protease inhibitor 
cocktail. The same amount of samples was pre-cleared 
with protein A-agarose IP reagent (sc-2001; Santa Cruz 
Biotechnology), and incubated with 2 µg of rabbit poly-
clonal primary antibodies for MR (sc-11412; Santa Cruz 
Biotechnology) for 1 h at 4 ˚C. MR-associated proteins 
were pulled-down with protein A-agarose IP reagent 
overnight at 4 ˚C, and washed 4 times in IP buffer. Im-
munoprecipitated proteins were eluted in Laemmli buf-
fer and Western blot analysis performed to detect ELL 
bound to MR by using the antibody for ELL.
 
[3H]proline incorporation into cardiac fibroblasts
To evaluate collagen synthesis, cardiac fibroblasts were 
incubated in medium supplemented with [3H]proline (1 
μCi/mL; Perkin Elmer, Waltham, MA) in the absence or 
presence of corticosterone (300 nmol/L).20 The effects 
of MR antagonist (eplerenone, 1 μmol/
L) on corticosterone-stimulated [3H]
proline incorporation were assessed in 
the absence or the presence of H2O2 (1 
μmol/L). After 48 h treatment, extracel-
lular proline was removed by aspiration 
of media, plates were washed twice 
with phosphate-buffered saline, and 5% 
cold trichloroacetic acid was added to 
solubilize intracellular free [3H]proline 
and precipitate [3H]proline incorporated 
into collagen. After 30 min, trichloro-
acetic acid was aspirated, plates were 
washed twice with 95% ethanol, and 0.5 
N NaOH was added to solubilize the 
precipitated proteins. After an additional 
30 min, scintillation cocktail (Insta-Gel 
Plus; Perkin Elmer) was added, and the 
radioactivity was measured in a liquid 
scintillation counter (LS 6500; Beckman 
Coulter, Brea, CA). The amount of [3H]
proline incorporation was normalized to 
the mean of the control.
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Fig. 2. The effect of H2O2 on the expression of ELL, MR and 11betaHSD2, and ELL-MR interaction in cultured cardiac fibroblasts.  Car-
diac fibroblasts were treated with H2O2 (1 μmol/L) for 48 h. Cardiac fibroblasts without H2O2 were served as Ctl.  
A: RT-qPCR was performed to evaluate the mRNA levels of ELL, MR and 11betaHSD2 in the cardiac fibroblasts (n = 5 for each group). 
B: WB analysis was performed to evaluate the protein levels of ELL and MR in the cardiac fibroblasts.  The images (upper) and the re-
sults of densitometry (lower) of WB analysis (n = 4 for each group). 
Ctl was arbitrarily set to 1.  Data are expressed as mean values ± SD.  
*P < 0.05 versus Ctl.
C: Cell lysate of cardiac fibroblasts was subjected to IP with anti-MR antibody.  Immunoprecipitates were subsequently analyzed by 
Western blotting with anti-ELL antibody.  
Ctl, control; ELL, elongation factor eleven-nineteen lysine-rich leukemia; IP, immunoprecipitation; RT-qPCR, real-time quantitative re-
verse transcriptase-PCR; MR, mineralocorticoid receptor; WB, Western blot.
Small interfering RNA-mediated knockdown of 
ELL
Cardiac fibroblasts from the second passage were trans-
fected with ELL small interfering RNA (siRNA) or with 
non-targeting control siRNA (B-Bridge International, 
Cupertino, CA) at a final concentration of 50 nmol/L 
with Lipofectamine RNAiMAX (Invitrogen) in DMEM 
supplemented with 10% charcoal stripped FCS without 
antibiotics according to the manufacturer’s instructions. 
The media were changed to DMEM supplemented with 
10 % charcoal stripped FCS and antibiotics 24 h after 
of siRNA transfection. The inhibitory efficiency of each 
siRNA was examined by measuring ELL mRNA levels 
by RT-qPCR 108 h after of siRNA transfection. Mea-
surement of [3H]proline incorporation into siRNA trans-
fected cardiac fibroblasts was performed.
 
Statistics 
Results are expressed as mean ± SD. Differences among 
groups were analyzed by one-way analysis of variance, 
followed by the Fisher protected least significant dif-




Corticosterone promotes collagen production via 
MR in oxidative stress in cardiac fibroblasts 
To investigate whether glucocorticoid promotes collagen 
production through MR, [3H]proline incorporation into 
cardiac fibroblasts was measured.
 Corticosterone increased [3H]proline incorporation 
into cardiac fibroblasts (Figs. 1A and B). The corticos-
terone-induced increase of [3H]proline incorporation 
was not changed by eplerenone in the absence of H2O2 
(Fig. 1A), but attenuated by eplerenone in the presence 
of H2O2 (Fig. 1B). Eplerenone alone did not affect the 
[3H]proline incorporation in either the absence or the 
presence of H2O2 (Figs. 1A and B). H2O2 alone did not 
affect the [3H]proline incorporation in the cardiac fibro-
blasts (data not shown). These results indicate that corti-
costerone increases collagen production through MR in 
cardiac fibroblasts under oxidative stress.
 
ELL expression and binding to MR are increased 
by oxidative stress in cardiac fibroblasts 
To investigate the effect of oxidative stress on the ELL 
expression levels and the ELL-MR interaction, cardiac 
113
Cardiac fibrosis through MR
Fig. 3. LV fibrosis, ROS generation, ELL expression and ELL-MR interaction in the LVs of 22 weeks old Dahl salt-sensitive rats.  
Representative photomicrographs of Azan Mallory staining to evaluate LV fibrosis (A) and representative immunohistochemical staining 
for 4-hydroxy-2-nonenal to evaluate ROS generation (B) in the LV of a Dahl-salt sensitive rat in the Ctl group and the HF group.  
C: RT-qPCR analysis of the mRNA levels of ELL in the LVs of Dahl salt-sensitive rats (n = 8 for each group).  
D: WB analysis of the protein levels of ELL in the LVs of Dahl salt-sensitive rats.  The images (left) and the results of densitometry (right) 
of WB analysis (n = 5 for each group). 
Data are expressed as mean values ± SD. The Ctl group was arbitrarily set to 1.  
*P < 0.05 versus the Ctl group. 
E: LV lysate of Dahl salt-sensitive rats was subjected to IP with anti-MR antibody.  Immunoprecipitates were subsequently analyzed by 
Western blotting with anti-ELL antibody.
Ctl, control; ELL, elongation factor eleven-nineteen lysine-rich leukemia; HF, heart failure; IP, immunoprecipitation; LV, left ventricle; 
MR, mineralocorticoid receptor; ROS, reactive oxygen species; WB, Western blot.
fibroblasts were incubated in the presence or absence of 
H2O2 (1 μmol/L) for 48 h.
 The mRNA and the protein levels of ELL were in-
creased in the cultured cardiac fibroblasts under oxida-
tive stress with H2O2 (Figs. 2A and B). IP assay revealed 
the presence of ELL-MR binding and that the amount 
of ELL bound to MR was increased in the cardiac fibro-
blasts incubated in the presence of H2O2 (Fig. 2C).
 The mRNA and protein levels of MR were un-
changed by H2O2 (Figs. 2A and B). 
 
ELL expression and binding to MR are increased in 
LV of HF rats with enhanced oxidative stress 
To evaluate the ELL expression levels and the interac-
tion between ELL and MR in in vivo heart, the LV of 
the HF rats were compared with those of control rats.
 Systolic blood pressure was elevated in the HF 
group than in the control group (224 ± 15 mmHg in the 
HF group versus 128 ± 7 mmHg in the control group, 
P < 0.05). The increased ratio of lung weight to tibial 
length indicated that the HF group developed overt 
congestive HF (83.3 ± 15.3 mg/mm in the HF group 
versus 36.8 ± 1.5 mg/mm in the control group, P < 0.05). 
Significant interstitial fibrosis was observed in the HF 
group (Fig. 3A) and the percent area of LV fibrosis was 
increased in the HF group compared with the control 
group (4.9 ± 0.4% in the HF group versus 2.2 ± 0.4% in 
the control group, P < 0.05). HNE staining revealed the 
increased ROS generation in the LV of the HF group (Fig. 
3B).
 Both mRNA and the protein levels of ELL were in-
creased in the LV of the HF group compared with con-
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Fig. 4. [3H]proline incorporation into cardiac fibroblasts after knockdown of ELL under oxidative stress.  
A: Cardiac fibroblasts were transfected with siELL (50 nmol/L, n = 3).  Cardiac fibroblasts transfected with siNT (50 nmol/L, n = 3) 
were served as control.  
B: Cardiac fibroblasts were transfected with siNT (50 nmol/L) with Cor (300 nmol/L) and/or Epl (1 μmol/L) in the presence of H2O2 
(1 μmol/L). Cardiac fibroblasts transfected with siNT in the presence of H2O2 were served as control.  n = 8 for each group.  
C: siELL transfected cardiac fibroblasts were treated with Cor (300 nmol/L) and/or Epl (1 μmol/L) in the presence of H2O2 (1 μmol/L). 
siELL transfected cardiac fibroblasts with H2O2 alone were served as control. n = 8 for each group.  
Control was arbitrarily set to 1. Data are expressed as mean values ± SD. 
*P < 0.05 versus control.
†P < 0.05 versus Cor (+) Epl (–) H2O2 (+).
#P < 0.05 versus Cor (–) Epl (+) H2O2 (+). 
Cor, corticosterone; ELL, elongation factor eleven-nineteen lysine-rich leukemia; Epl,  eplerenone; siELL, ELL siRNA; siNT, non-target-
ing control siRNA.
trol (Figs. 3C and D). IP assays revealed that the amount 
of ELL bound to MR was increased in the LVs of the 
HF group (Fig. 3E). 
MR blockade did not inhibit corticosterone-induced 
collagen production after knockdown of ELL in 
cardiac fibroblasts 
[3H]proline incorporation into cardiac fibroblasts in-
duced by corticosterone was evaluated after knockdown 
of ELL expression using siRNA for ELL, to investigate 
the role of ELL in glucocorticoid-induced collagen pro-
duction.
 The ELL mRNA levels in cardiac fibroblasts were 
significantly decreased after the transfection of ELL 
siRNA compared with non-targeting control siRNA (Fig. 
4A). Corticosterone increased [3H]proline incorporation, 
and this increase was attenuated by eplerenone in the 
presence of H2O2 with non-targeting control siRNA (Fig. 
4B). However, the corticosterone-induced increase of 
[3H]proline incorporation was not attenuated by eplere-
none in the presence of H2O2 after knockdown of ELL 
by siRNA (Fig. 4C). These results suggest that ELL 
enables corticosterone to promote collagen production 
through MR under oxidative stress. 
 
DISCUSSION
In this study, we showed that i) corticosterone promoted 
collagen production via MR in the presence of oxida-
tive stress in cardiac fibroblasts, ii) ELL expression 
levels and MR-bound ELL were increased in cardiac 
fibroblasts in oxidative stress, iii) ELL expression levels 
and MR-bound ELL were increased in LV of HF rats by 
oxidative stress and iv) knockdown of ELL expression 
blunted the corticosterone-induced collagen production 
via MR in oxidative stress in cardiac fibroblasts.
 Although it has been suggested that glucocorticoids 
can function to work as an MR ligand in the heart, it is 
still uncertain how glucocorticoids act via MR in the 
diseased heart and contribute to the development of HF. 
Glucocorticoids occupy cardiac MR without obvious 
mineralocorticoid-like effects in normal conditions,8 
but may activate MR under particular condition such as 
oxidative stress.5, 12–14 Our previous study demonstrated 
that blockade of MR attenuated cardiac fibrosis and 
prevented HF in the HF model rats with low cardiac al-
dosterone levels.6 In the present study, we expanded the 
previous studies by demonstrating that corticosterone 
can increase collagen production via MR in oxidative 
stress. Therefore, blockade of MR may protect cardiac 
MR from corticosterone, reduce cardiac fibrosis, and 
prevent the development of HF with enhanced oxidative 
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stress. In the absence of H2O2, corticosterone induced 
collagen production without the inhibition by eplerenon 
in this in vitro study. Corticosterone can also bind to glu-
cocorticoid receptor. Our previous study showed that the 
expression of glucocorticoid receptor was upregulated 
in the hypertrophied heart but the role of the glucocorti-
coid receptor on cardiac fibrosis was not clear.19 Further 
studies are required to clarify the role of glucocorticoid 
receptor and MR on in vivo cardiac fibrosis. 
 In non-epithelial tissues such as heart, the expres-
sion of 11betaHSD2 which inactivates glucocorticoid to 
inactive form is negligibly low.5, 6 In the present study, 
11betaHSD2 protein levels were undetermined because 
of its very low expression level in cultured cardiac fibro-
blasts (data not shown). The MR expression levels were 
also unchanged by oxidative stress in cultured cardiac 
fibroblasts. Therefore, it suggests that corticosterone 
can promote collagen synthesis via MR under oxidative 
stress independently of 11betaHSD2 or MR expression 
levels. At the post-receptor level several co-activators of 
MR other than ELL have been reported;25–29 we have 
not investigated the involvement of these factors and 
their interaction with ELL in the present study. 
 In cardiac myocytes, glucocorticoids have been 
reported to increase beating frequency via MR in oxida-
tive stress,30, 31 but has not been elucidated how oxida-
tive stress modulates MR response to glucocorticoid. In 
the present study, knockdown of ELL can at least par-
tially decrease the MR response to corticosterone under 
oxidative stress. ELL, a co-activator of MR, enhances 
MR transcriptional activity by both glucocorticoids and 
mineralocorticoids.16 In the present study, ELL expres-
sion levels and the amount of ELL bound to MR were 
increased in cultured cardiac fibroblasts in oxidative 
stress; corticosterone did not promote collagen synthe-
sis through MR after knockdown of ELL expression. 
These results indicate that ELL may contribute to the 
development of cardiac fibrosis by co-activating MR 
with corticosterone under oxidative stress. In this study, 
we did not show how ELL expression levels and ELL-
MR binding were changed under oxidative stress and 
further investigation should clarify those mechanisms. 
The ELL expression and the amount of ELL bound to 
MR were increased in the LV of the HF model rats, and 
associated with increased cardiac fibrosis and enhanced 
oxidative stress. Given that glucocorticoid activity via 
MR and ELL expression were increased together in 
oxidative stress, it suggests that ELL may contribute to 
the MR activation in the development of cardiac fibrosis 
and HF in vivo. Although the mechanism of the regula-
tion of ELL expression was unknown, it is possible that 
some therapeutic approaches reduce ELL expression and 
affect the MR dependent cardiac fibrosis. Cardiac condi-
tional KO of ELL gene might also elucidate the function 
of ELL and coticosterone in cardiac fibrosis of in vivo 
heart.
 Serum cortisol has also been reported as a useful 
predictor of cardiac events in patients with HF, but there 
is not enough evidence showing cardiac fibrosis in pa-
tients with high serum glucocorticoid such as Cushing 
syndrome or connective tissue diseases with steroid 
therapy. It is possible that high serum concentration of 
glucocorticoid has a different effect on the heart from a 
local increase of corticosterone in cardiac tissue while 
a local increase of corticosterone in cardiac tissue has a 
role in cardiac fibrosis in the presence of oxidative stress 
in the in vivo heart.
 In summary, our present study indicates that corti-
costerone promotes cardiac fibrosis via MR in oxidative 
stress, and this corticosterone-induced cardiac fibrosis is 
at least partially modulated by ELL. Preventing cardiac 
fibrosis by modulating glucocorticoid-MR-ELL path-
ways may thus become a new therapeutic strategy for 
HF.
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